Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Line Clear all
Completed Phase 1 Interventional

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

NCT01735968
View directory record Official record
Conditions
3rd Line GIST
Interventions
ST571 + BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 30, 2026, 10:21 AM EDT
Not yet recruiting Not applicable Interventional

Miniature In-line Respirator

NCT07768215
View directory record Official record
Conditions
Brain Death, Respiration, Artificial
Interventions
Hope inVent
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
1 Year to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 10:21 AM EDT
Withdrawn No phase listed Observational

Comparison of Techniques for Assessing Cardiac Output and Preload in Critically Ill Pediatric Patients

NCT00167440
View directory record Official record
Conditions
Low Cardiac Output
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
Up to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 30, 2026, 10:21 AM EDT
Completed No phase listed Observational Results available

A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients

NCT02086682
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Complication of Dialysis, Blood Coagulation Disorders
Interventions
Not listed
Lead sponsor
Marie Hogan
Other
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 30, 2026, 10:21 AM EDT
Active, not recruiting Not applicable Interventional

The Arteriovenous Vascular (AV) ACCESS Trial

NCT04646226
View directory record Official record
Conditions
End-Stage Kidney Disease, Hemodialysis Complication
Interventions
AV graft, surgical intervention for creation of a fistula
Device · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 30, 2026, 10:21 AM EDT
Terminated Phase 2 Interventional Results available

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

NCT04003610
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 30, 2026, 10:21 AM EDT
Completed No phase listed Observational

Study Examining the Effect of a Novel Cannulation Knife on User Satisfaction and Common Central Venous Catheter Insertion Complications

NCT06310174
View directory record Official record
Conditions
Central Venous Catheter Exit Site Infection
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
86 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.

NCT05955586
View directory record Official record
Conditions
Healthy Volunteer
Interventions
SPR720
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 30, 2026, 10:21 AM EDT
Completed No phase listed Observational

Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease

NCT00351156
View directory record Official record
Conditions
Gaucher Disease
Interventions
Blood sample
Procedure
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
San Francisco, California • Coral Springs, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 30, 2026, 10:21 AM EDT
Terminated Phase 2 Interventional Results available

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

NCT00718523
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
AMG 479, AMG 479 Placebo
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
23
States / cities
Alhambra, California • Burbank, California • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

NCT01663727
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Bevacizumab [Avastin], Paclitaxel, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
66
States / cities
Birmingham, Alabama • Tucson, Arizona • Corona, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

NCT00073515
View directory record Official record
Conditions
Catheters, Indwelling
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Not applicable Interventional Results available

Community Central Line Infection Prevention Trial

NCT02351258
View directory record Official record
Conditions
Infection
Interventions
70% Isopropyl alcohol embedded caps, Usual Care
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Day to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 30, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

NCT07406633
View directory record Official record
Conditions
GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour, Gastrointestinal Tumors
Interventions
KQB198, Imatinib (Gleevec)
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Not applicable Interventional Results available

Study of ECHELON ENDOPATH(TM) Staple Line Reinforcement

NCT04544865
View directory record Official record
Conditions
Gastric Procedures, Lung Resection Procedures
Interventions
Staple Line Reinforcement
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • Baton Rouge, Louisiana • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 30, 2026, 10:21 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07043400
View directory record Official record
Conditions
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU), Oxaliplatin, Capecitabine
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Chandler, Arizona • Los Alamitos, California • Colorado Springs, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer

NCT00408603
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Voreloxin Injection
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Scottsdale, Arizona • Newport Beach, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Not applicable Interventional

The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants

NCT00964093
View directory record Official record
Conditions
Central Line Bloodstream Infections
Interventions
Silver Alginate
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
1 Day to 3 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 30, 2026, 10:21 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Implementation of Ultrasound Guided Central Venous Catheter Confirmation Protocol

NCT04324762
View directory record Official record
Conditions
Behavior, Process, Acceptance, Inertia of Accommodation
Interventions
targetted implementation strategies
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 30, 2026, 10:21 AM EDT
Terminated Not applicable Interventional Results available

Assessment of the Precision of the Sherlock 3CG Tip Positioning System

NCT01275430
View directory record Official record
Conditions
No Specific Conditions Under Study. Primary Focus: Adult Subjects Who Require PICC Placement
Interventions
Sherlock 3CG, Blind Placement
Device · Other
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 30, 2026, 10:21 AM EDT
Terminated No phase listed Observational

A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture

NCT02402829
View directory record Official record
Conditions
Hemophilia A, Factor VIII Deficiency, Hemophilia, Hemophilia B, Factor IX Deficiency
Interventions
Peripheral Vein Blood draw
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 21 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters

NCT00231153
View directory record Official record
Conditions
Infection
Interventions
Omiganan 1% gel, Povidone-Iodine 10%
Drug
Lead sponsor
Cadence Pharmaceuticals
Industry
Eligibility
13 Years and older
Enrollment
1,859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
36
States / cities
Mobile, Alabama • Phoenix, Arizona • Arcadia, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2009 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines

NCT02184988
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum purified neurotoxin, Type A
Biological
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 30, 2026, 10:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

NCT04203160
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
CPI 613, Gemcitabine, Cisplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 30, 2026, 10:21 AM EDT